Nearly two years in with Zurzuvae, Biogen tackles an ‘all of the above market’ to find patients and battle stigma in ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal. Specific details of the lawsuit are not yet available ...

Biogen ( NASDAQ: BIIB) and City Therapeutics signed a collaboration to develop novel RNA interference ( (RNAi)) therapies ...

A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs.

Biogen will pay City Therapeutics $46m, which includes $16m upfront and $30m investment for a convertible note.

Big Biotech Biogen is venturing into the city, paying $16 million in cash to partner up with an RNAi company to build ...

Biogen Inc. (NASDAQ: BIIB )’s recent partnership with City Therapeutics, Inc. to develop RNAi therapies for central nervous ...

CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference ...

Biogen and City Therapeutics are collaborating to develop select RNAi therapies in a $46 million partnership. City Therapeutics, a private biopharmaceutical company, will offer its RNAi-engineering ...

A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments.